While we wait for public orthopedic companies to announce 2025 first quarter results, we take a look at how the market finished in 2024, resurgent M&A volume early in the year and the potential impact of tariffs on the orthopedic industry.
Mike Evers is an analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage. You can reach him by email.
While we wait for public orthopedic companies to announce 2025 first quarter results, we take a look at how the market finished in 2024, resurgent M&A volume early in the year and the potential impact of tariffs on the orthopedic industry. Mike Evers is an analyst and writer with over 15 years of...
While we wait for public orthopedic companies to announce 2025 first quarter results, we take a look at how the market finished in 2024, resurgent M&A volume early in the year and the potential impact of tariffs on the orthopedic industry.
Mike Evers is an analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage. You can reach him by email.
You are out of free videos for this month
Subscribe as a Guest for $0 and unlock a total of 5 videos per month.
You are out of five videos for this month
Subscribe as an Executive Member for access to unlimited videos, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.